Stonekeep Investments LLC Buys 882 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Stonekeep Investments LLC raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,952 shares of the company’s stock after purchasing an additional 882 shares during the period. Stonekeep Investments LLC’s holdings in Hims & Hers Health were worth $410,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Main Management ETF Advisors LLC bought a new stake in Hims & Hers Health during the third quarter worth approximately $672,000. Robeco Institutional Asset Management B.V. bought a new stake in Hims & Hers Health in the third quarter worth $604,000. Carnegie Investment Counsel purchased a new position in Hims & Hers Health during the third quarter worth $5,531,000. Royce & Associates LP increased its position in Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Finally, Versor Investments LP purchased a new position in shares of Hims & Hers Health during the third quarter worth approximately $634,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $22.20, for a total transaction of $166,500.00. Following the sale, the insider now directly owns 193,980 shares in the company, valued at approximately $4,306,356. This represents a 3.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This trade represents a 1.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,080,208 shares of company stock valued at $29,106,823 in the last quarter. Insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of a number of research analyst reports. Piper Sandler lifted their target price on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Morgan Stanley started coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Needham & Company LLC lifted their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Finally, Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Stock Down 0.5 %

Shares of HIMS opened at $27.80 on Friday. The firm’s fifty day moving average is $27.68 and its two-hundred day moving average is $21.85. The stock has a market cap of $6.07 billion, a PE ratio of 63.19 and a beta of 1.31. Hims & Hers Health, Inc. has a 52-week low of $8.14 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the business posted ($0.04) earnings per share. The firm’s revenue was up 77.1% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.